Authors: Jones, R.M.; Bulaj, G.

Source: Current Drug Metabolism, Volume 6, Number 12, 1 August 2000 , pp. 1249-1285(37)

Publisher: Bentham Science Publishers

Abstract:

There are approximately 500 species of predatory cone snails within the genus Conus. They comprise what is arguably the largest single genus of marine animals alive today. It has been estimated that the venom of each Conus species has between 50 and 200 components. These highly constrained sulfur rich components or conotoxins represent a unique arsenal of neuropharmacologically active peptides that have been evolutionarily tailored to afford unprecedented and exquisite selectivity for a wide variety of ion-channel subtypes. Remarkable divergence occurs when cone snails speciate. Consequently, the complement of venom peptides in any one Conus species is distinct from that of any other species. Hence many thousands of peptides that modulate ion channel function are present within Conus venoms. Evolutionary pressures have afforded a pre-optimized, structurally sophisticated library that has been fine tuned over 50 million years. The statistics associated with sampling such libraries bear testimony to the validity and feasibility of this strategy. Although approximately 100 conotoxin sequences have been published in the scientific literature, representing a mere 0.2 pecent of the estimated library size, this sample has already afforded a peptide of proven clinical utility and several pre-clinical leads for CNS disorders. Conus libraries represent a rich pharmacopoeia and the potential to therapeutically mine such a resource appears limitless. The paucity of synthetic methodologies necessary to achieve the regioisomeric folding patterns present in these native peptides precludes access to synthetic conotoxin libraries, further validating the overall mining strategy. In this article, we will present a pragmatic overview of the molecular diversity as well as the neurobiological mechanisms that define each major class of conotoxin.

Keywords: Conotoxins; Peptide Therapeutics; Conantokins; Contulakins; Conodipines; Phospholipid; Phyllomedusa; Agelenopsis aperta; Conus episcopatus; Conus radiatus; Contryphan and Bromocontryphan; Disulfide templates; ICK; Channel recognition motif; Potassium Channel Selective Conotoxins; Pisciorous Conus; Sodium channel selective conotoxins; Conus purpurascens; Prostate cancer; Epilepsy; Anticonvulsants

Document Type: Review article

DOI: http://dx.doi.org/10.2174/1381612003399653

Publication date: 2000-08-01

More about this publication?

• Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. A Guest Editor who is an acknowledged authority in a therapeutic field has solicits for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia.
  
  Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism.

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Jones, R.M. ;  Bulaj, G.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers